Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

Methylome End to End Samples Processing Services

Awarded
36C26226P1118Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

Twist Bioscience Corporation, recognized as a small business with unique capability, has been sole-source awarded for Methylome End to End Samples Processing Services under solicitation 36C26226P1118 due to its exclusive ability to deliver high-end methylome sequencing services requiring enzyme-linked target sequencing, specific experimental protocols, and methylation panels, all while generating high-quality libraries from just 60 ng of cell-free DNA with a non-CpG conversion rate exceeding 99%. No other vendor can meet these highly specialized technical requirements without jeopardizing the validity, accuracy, and success of the research, as demonstrated by the successful completion of prior work with the same provider. The contract was issued in accordance with FAR 13.106-1(b)(1) to ensure continuity and reliability, with performance to be conducted at Twist Bioscience’s facility in South San Francisco, California, while the contracting office is located in Gilbert, Arizona, under the Department of Veterans Affairs, 262-NETWORK Contract Office 22.

General Info

Twist Bioscience sole-source awarded for high-accuracy methylome sequencing using 60 ng cfDNA with 99%+ non-CpG conversion.

Agency

Department Of Veterans Affairs → 262-NETWORK Contract Office 22 (36C262)View Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

South San Francisco, CA, 94080, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseAwarded
Posted

Award Notice

Awarded

Contract was awarded

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Veterans Affairs → 262-NETWORK Contract Office 22 (36C262)
ContactsNo contacts available
OfficeGilbert, AZ, 85297, USA
Organization / Agency
Department Of Veterans Affairs → 262-NETWORK Contract Office 22 (36C262)
View Agency Profile
Office AddressGilbert, AZ, 85297, USA
ContactsNo contact information available

Full Description

Show more

Twist Bioscience Coproation, who are a small business, are the only vendor capable of providing the specific high end Methylome Sequencing services which include enzyme-linked target sequencing, specific experimental protocol and methylation panels, along with a high-quality library from 60 ng cell-free DNA for Methylome sequencing with a non-CpG conversion rate >99%. 


Selecting another company for this magnitude of sequencing and sampling would put the research effectiveness and accuracy in jeaopardy, and would compromise the entire study. Twist Bioscience was used in a preivous study, all the goals setforth were achieved. This was awarded IAW FAR 13.106-1(b)(1).


Similar Contracts

NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: Platform to Accelerate Discovery of Tailored Industrial Enzymes (PAD-TIE)The PAD-TIE platform, developed by NREL and Los Alamos National Laboratory, is a high-throughput screening system designed to rapidly identify and optimize enzymes capable of breaking down polyethylene terephthalate (PET) plastic under industrially relevant conditions. Unlike traditional methods that test enzymes one at a time, PAD-TIE evaluates tens of thousands of enzyme variants simultaneously, measuring their activity, stability, and production efficiency in a single process, eliminating costly purification steps and reducing time-to-identification. The system operates at the optimal temperature for PET degradation and is validated in lab-scale bioreactors that mimic real-world recycling environments, enabling the conversion of plastic waste into reusable monomers without harsh chemicals or excessive energy use. With a Technology Readiness Level of 6, the platform is a fully functional prototype with all components tested, and three U.S. patents are pending, making it a mature and protected innovation ready for commercial adoption. PAD-TIE is positioned to serve a broad range of industries including plastic recycling, waste management, polymer manufacturing, and sustainable materials development. Its adaptability allows customization for different PET compositions, additives, and processing conditions, ensuring compatibility with existing infrastructure. The platform’s efficiency and scalability offer a cost-effective solution for scaling enzymatic plastic degradation at an industrial level. Los Alamos National Laboratory is seeking industry partners through exclusive or non-exclusive licensing agreements to further develop and deploy the technology, with applications spanning bioremediation, bioplastics, and closed-loop recycling systems. Interested parties must respond by October 1, 2026, and inquiries should be directed to the provided licensing contacts. The technology is available for commercialization under a non-set-aside procurement with a NAICS code of 541714, and performance will occur in Los Alamos, New Mexico.
Triad - DOE Contractor

POSTED

4 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Federal
RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)The Biomedical Advanced Research and Development Authority (BARDA) is seeking proposals under solicitation 75A50126R00002 to develop, obtain regulatory approval for, and procure approximately two million 2-PAM (600mg) autoinjectors as a drug/device combination product for the treatment of organophosphate poisoning, including nerve agents, in both adult and pediatric populations. This effort supports the Strategic National Stockpile (SNS) and CHEMPACK Program. The contract is structured as a hybrid cost-plus-fixed-fee and firm-fixed-price instrument with an anticipated base performance period of up to 36 months and potential extension through options to a total duration of eight years. Key deliverables include late-stage clinical development, regulatory submission and approval, and large-scale manufacturing of autoinjectors, with production split across multiple CLINs totaling 2 million units. The solicitation is issued as a Statement of Objectives, requiring offerors to submit a comprehensive Statement of Work and Risk Mitigation Plan addressing program management, product development, supply chain logistics, and optional post-marketing commitments. Manufacturing and packaging must adhere to Good Manufacturing Practice regulations under 21 CFR Part 820, and all products must maintain strict temperature controls during transit, with ambient exposure logging required from the offeror’s validated facility until acceptance by the government at the ASPR/SNS location in Washington, D.C. All proposals must comply with mandatory eligibility criteria, including adherence to FAR and HHSAR clauses covering cost allowability, inspection, intellectual property, anti-kickback, and contingency fee restrictions. Offerors are required to complete SAM.gov representations and certifications, submit a detailed organizational chart identifying key personnel including a Program Director, Chief Scientific/Medical Officer, Manufacturing Lead, Regulatory Affairs Lead, and Project Manager, and demonstrate compliance with human subject protections under 45 CFR 46. Security requirements mandate layered physical controls, identification verification for personnel and visitors, and robust information and cyber security protocols encompassing access controls, intrusion detection, and encryption. Proposals must be submitted by July 30, 2026, and remain firm for 120 days. Evaluation will prioritize technical merit, past performance, and overall value over cost, with non-cost factors carrying significantly greater weight. Contract administration requires electronic invoice submissions via the Treasury IPP system to designated federal offices and strict adherence to documentation handling, packaging, and delivery protocols. The procurement is open to all qualified entities without set-aside restrictions
Barda - Aspr / Daappo / Barda Dcma

POSTED

4 days ago

DEADLINE

in 18 days
View Details